Davis's Drug Guide
capivasertib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
kap-eye-va-ser-tib
Trade Name(s)
- Truqap
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Capivasertib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110969/6/capivasertib.
Vallerand AHA, Sanoski CAC, . Capivasertib. Davis's Drug Guide. F.A. Davis Company; 2025. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110969/6/capivasertib. Accessed November 2, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Capivasertib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110969/6/capivasertib
Vallerand AHA, Sanoski CAC, . Capivasertib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 November 02]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110969/6/capivasertib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - capivasertib
ID - 110969
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110969/6/capivasertib
PB - F.A. Davis Company
ET - 19
DB - Nursing Central
DP - Unbound Medicine
ER -
